舒马曲普坦治疗偏头痛发作与中枢5-HT1B受体结合的关系
该研究纳入8例无先兆发作性偏头痛患者,采用自身对照设计,通过[11C]AZ10419369 PET扫描评估舒马曲普坦对中枢5-HT1B受体的占据率及偏头痛发作期间脑内5-HT1B受体结合变化。结果显示舒马曲普坦与疼痛调节区域5-HT1B受体结合显著降低相关,平均占据率为16.0%,且偏头痛发作期间5-HT1B受体结合较发作间期显著降低。
要点
- 舒马曲普坦皮下注射6mg后疼痛调节区域5-HT1B受体平均占据率为16.0%。
- 偏头痛发作期间5-HT1B受体结合较发作间期显著降低,提示内源性5-羟色胺释放增加。
- 舒马曲普坦可进入中枢神经系统并与5-HT1B受体结合,可能是其急性治疗偏头痛的机制之一。
核心结论
- 偏头痛发作期间给予舒马曲普坦与中枢5-HT1B受体结合降低相关,最可能与舒马曲普坦占据中枢5-HT1B受体有关,但不能排除发作期间内源性5-羟色胺释放的贡献。
研究设计与样本
- 研究在丹麦进行,采用自身对照设计,纳入8例未治疗的无先兆发作性偏头痛患者,年龄18至65岁,来自普通社区。
- 所有参与者接受3次[11C]AZ10419369 PET扫描:偏头痛发作期、皮下注射6mg舒马曲普坦后、以及无偏头痛发作日,每次扫描持续90分钟。
主要发现
- 舒马曲普坦给药后,疼痛调节区域5-HT1B受体结合潜力均值(标准差)从1.20(0.20)降至1.02(0.22),差异有统计学意义(P = .001)。
- 舒马曲普坦的平均(标准差)药物占据率为16.0%(5.3%)。
- 偏头痛发作期间较发作间期,疼痛调节区域5-HT1B受体结合潜力均值(标准差)从1.36(0.22)降至1.20(0.20),差异有统计学意义(P = .02)。
临床怎么用
- 该研究提示舒马曲普坦急性治疗偏头痛可能通过占据中枢5-HT1B受体发挥作用,但样本量小,尚不能直接指导临床剂量调整。
局限性
- 样本量仅8例,其中7例为女性,结果外推需谨慎。
- 不能排除偏头痛发作期间内源性5-羟色胺释放对5-HT1B受体结合降低的贡献。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Triptans, the most efficient acute treatment for migraine attacks, are 5-HT1B/1D receptor agonists, but their precise mechanism of action is not completely understood. The extent to which triptans enter the central nervous system and bind to 5-HT1B receptors in the brain is unknown. OBJECTIVES: To determine the occupancy of sumatriptan to central 5-HT1B receptors, and to investigate changes in brain serotonin levels during migraine attacks. DESIGN, SETTING, AND PARTICIPANTS: This study of 8 patients in Denmark used a within-participant design and was conducted from April 20, 2015, to December 5, 2016. Participants were otherwise healthy patients with untreated episodic migraine without aura, aged between 18 and 65 years, and recruited from the general community. Data analysis was performed from January 2017 to April 2018. INTERVENTIONS: All participants underwent positron emission tomographic scans after injection of [11C]AZ10419369, a specific 5-HT1B receptor radiotracer. All participants were scanned 3 times: (1) during an experimentally induced migraine attack, (2) after a subcutaneous injection of 6-mg subcutaneous sumatriptan, and (3) on a migraine attack-free day. Scans 1 and 2 were conducted on the same study day. Each scan lasted for 90 minutes. MAIN OUTCOME AND MEASURE: The primary outcome was the nondisplaceable binding potential of [11C]AZ10419369 across 7 brain regions involved in pain modulation. The binding potential reflects receptor density, and changes in binding potential reflects displacement of the radiotracer. The occupancy of sumatriptan was estimated from the 2 scans before and after sumatriptan administration. RESULTS: Eight patients with migraine were included in the study; of these participants, 7 (87%) were women. The mean (SD) age of participants on study day 1 was 29.5 (9.2) years and on study day 2 was 30.0 (8.9) years. Sumatriptan was associated with statistically significantly reduced 5-HT1B receptor binding across pain-modulating regions (mean [SD] binding potential, 1.20 [0.20] vs 1.02 [0.22]; P = .001), corresponding to a mean (SD) drug occupancy rate of 16.0% (5.3%). Furthermore, during migraine attacks, as compared with outside of attacks, 5-HT1B receptor binding was statistically significantly associated with reduced in pain-modulating regions (mean [SD] binding potential, 1.36 [0.22] vs 1.20 [0.20]; P = .02). CONCLUSIONS AND RELEVANCE: Treatment with sumatriptan during migraine attacks appeared to be associated with a decrease in 5-HT1B receptor binding, a finding that is most likely associated with the binding of sumatriptan to central 5-HT1B receptors, but the contribution of ongoing cerebral serotonin release to the lower binding cannot be excluded; the migraine attack-associated decrease in binding could indicate that migraine attacks are associated with increases in endogenous serotonin.
引用
- Deen M, Hougaard A, Hansen HD, et al. Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT1B Receptor Binding. JAMA Neurol. 2019. PMID: 31135819. doi:10.1001/jamaneurol.2019.0755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。